Table 2.
Linear regression analysis of variables associated with a > 50% rise in P-creatinine at 48 h or 4–10 days after contrast-enhanced CT
| Variablea | Nr subjects at 48 h / Nr subjects at 4–10 days after CT | Above or below median value | P-creatinine rise 26.5 μmol/L or > 50% at 48 h after CT, OR (95% CI) | p-value | P-creatinine rise 26.5 μmol/L or > 50% and/or RRT initiation at 4–10 days after CT, OR (95% CI) | p-value |
|---|---|---|---|---|---|---|
| Male sex | 114/93 | 1.2 (0.2–6) | 0.86 | 3.0 (0.3–26) | 0.25 | |
| Age (years) | 114/102 | > 59 | 2.2 (0.5–9.4) | 0.27 | 4.7 (0.9–24) | 0.042 |
| Thromboembolic treatment | 114/93 | 0.59 (0.1–2.6) | 0.49 | 0.95 (0.2–5) | 0.96 | |
| Renal disease | 112/91 | 4.2 (0.4–46) | 0.29 | 6.8 (0.5–90) | 0.19 | |
| Type 2 diabetes | 111/90 | 3.3 (0.8–14) | 0.11 | 0.8 (0.1–7) | 0.80 | |
| P-creatinine (μmol/L) at CT | 114/93 | > 67 | 1.7 (0.4–6.7) | 0.46 | 2.4 (0.6–11) | 0.22 |
| CRP at CT scan (mg/L) | 113/92 | > 93 | 3.8 (0.7–19) | 0.08 | 6.8 (0.8–60) | 0.039 |
| Dose/weight (ml/kg) | 89/70 | > 0.78 | 0.68 (0.14–3.3) | 0.63 | 0.9 (0.2–3.9) | 0.86 |
| eGFR≥30–60 and contrast-enhanced CT | 114/93 | 5.7 (1.3–24) | 0.018 | 10.4 (2.3–47) | 0.002 | |
| ICU care | 113/92 | 2.0 (0.5–8) | 0.34 | 5.7 (1.2–27) | 0.023 | |
| 30-day mortality | 114/93 | 12 (2.7–54) | < 0.001 | 16 (3–79) | < 0.001 | |
| Renal replacement therapy at CTb | 128/106 | 4.7 (1.2–18) | 0.037 | 5.2 (1.4–19) | 0.017 |
a Patients performing contrast-enhanced CT, excluding subjects on renal replacement therapy.
b Including patients on renal replacement therapy.
CI confidence interval, CRP C-reactive protein, CT computed tomography, eGFR estimated glomerular filtration rate (ml/min × 1.73 m2), h hours, ICU intensive care unit, OR odds ratio, Nr Number, P-creatinine plasma creatinine, RRT renal replacement therapy